3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
72
Breast Neoplasms
9
Neoplasm Metastasis
8
Prostatic Neoplasms, Castration-Resistant
6
Neoplasms
5
Metastatic Castration-resistant Prostate Cancer
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Prostate Cancer Metastatic
3
Metastatic Castration Resistant Prostate Cancer
3
Bulbo-Spinal Atrophy, X-Linked
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Metastatic Hormone Sensitive Prostate Cancer
2
Melanoma
2
mCRPC
1
Urinary Bladder Diseases
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Ureteral Diseases
1
Solid Tumours
1
Small Cell Lung Carcinoma
1
Seizures
1
Salivary Cancer
1
Recurrent Endometrial Endometrioid Adenocarcinoma
1
Pancreatic Neoplasms
1
Non-metastatic, Hormone naïve Prostate Cancer
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms, Squamous Cell
1
Metastatic Progressive Castration-resistant Prostate Cancer
1
Interventions
Paclitaxel
19
pembrolizumab
16
Carboplatin
12
Bevacizumab
8
lenvatinib
6
rucaparib
5
Nivolumab
5
Megestrol Acetate
5
Radiation
4
Indocyanine Green
4
Gemcitabine
4
Cisplatin
4
tisotumab vedotin
3
temsirolimus
3
Sirolimus
3
Sentinel Lymph Node Biopsy
3
Magnetic Resonance Spectroscopy
3
Doxorubicin
3
olaparib
2
niraparib
2
ixabepilone
2
iso-sulfan blue
2
irosustat
2
epacadostat
2
durvalumab
2
copanlisib
2
Trastuzumab
2
Taxes
2
Specimen Handling
2
Radiotherapy, Intensity-Modulated
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Endometrial Neoplasms
×
enzalutamide
×
Clear all
No trials found.